Sichuan Huiyu Pharmaceutical
Sichuan Huiyu Pharmaceutical is a China-based pharmaceutical company that leads 5 cancer trials in OnCo, testing the in-house candidates HY0001a, HY05350, HY07121, HYP-6589 and HYP-2090 in advanced solid tumours.
Overview
Sichuan Huiyu Pharmaceutical is a research-driven pharmaceutical company that develops, manufactures and sells anti-tumour and injectable medicines for global markets, with a growing pipeline of in-house innovative drugs and a UK subsidiary, Seacross Pharma. It is listed on the Shanghai Stock Exchange STAR Market. On ClinicalTrials.gov it is the lead sponsor of 5 trials recorded in OnCo: NCT07069062 (phase 1/2, A Phase I/Ⅱ Human Study of HY0001a for Injection in Adult Participants With Advanced So...), NCT07083323 (phase 1/2, A Phase I/II Study of HY05350 in Mesothelin(MSLN)-Positive Advanced Solid Tumors), NCT06712680 (phase 1/2, A Phase I/II Study of HYP-6589 Monotherapy in Treating Advanced Solid Tumors and in Com...), NCT06639256 (phase 1/2, Phase 1/2 Clinical Study of HY07121 Powder for Solution for Infusion in Patients With A...) and NCT06243354 (phase 1/2, Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS M...). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.